Get the Stockscreener App
0.7151
2.30%
0.0161
After Hours:
.70
-0.0151
-2.11%
Cero Therapeutics Holdings Inc stock is traded at $0.7151, with a volume of 2.04M.
It is up +2.30% in the last 24 hours and down -50.17% over the past month.
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
See More
Previous Close:
$0.699
Open:
$0.68
24h Volume:
2.04M
Relative Volume:
2.45
Market Cap:
$2.17M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.78%
1M Performance:
-50.17%
6M Performance:
-92.33%
1Y Performance:
-99.63%
1-Day Range:
$0.68
$0.89
1-Week Range:
$0.65
$0.89
52-Week Range:
$0.65
$213.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Name
Cero Therapeutics Holdings Inc
Sector
Industry
Phone
650-407-2376
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare CERO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
0.7151 | 2.17M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cero Therapeutics Holdings Inc Stock (CERO) Latest News
CERo Therapeutics Delays Yearly Report Filing - TipRanks
FDA greenlights CERo’s Phase 1 trial for novel cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics Receives FDA Clearance For Second Clinical Trial Of CER-1236 In Solid Tumors - Nasdaq
CERo Gets FDA Clearance for CER-1236 Trial in Solid Tumors - MarketScreener
FDA greenlights CERo’s Phase 1 trial for novel cancer therapy - Investing.com India
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors - The Manila Times
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of - GlobeNewswire
Groundbreaking CAR-T Cancer Therapy Advances: FDA Greenlights Dual-Action Trial - Stock Titan
CERo Therapeutics gears up for clinical trial of cancer therapy By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.74 amid market challenges By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.74 amid market challenges - Investing.com Australia
CERo Therapeutics gears up for clinical trial of cancer therapy - Investing.com India
CERo Therapeutics Holdings, Inc. Poised to Initiate - GlobeNewswire
FDA Green Light: CERo's Leukemia Drug CER-1236 Advances to Human Trials with Optimized Manufacturing - Stock Titan
CERo Therapeutics (NASDAQ:CERO) Trading 4.6% Higher – Here’s What Happened - Defense World
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish - NewsBreak: Local News & Alerts
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Ca - Asianet Newsable
CERO Flat on Leukemia Drug Developments - Baystreet.ca
CERo Therapeutics partners with UC Davis for AML trial By Investing.com - Investing.com South Africa
CERo Therapeutics partners with UC Davis for AML trial - Investing.com
Restaurant Brands International to Report First Quarter 2025 Results on May 8, 2025 - The Globe and Mail
CERo Therapeutics Announces Manufacturing Agreement with UC Davis Ahead of Phase 1 Clinical Trial for AML - Nasdaq
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - GlobeNewswire
CERo Therapeutics reveals promising preclinical ovarian cancer study By Investing.com - Investing.com Australia
CERo Therapeutics reports positive preclinical results for cancer treatment By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Understanding CERO’s financial ratios: A beginner’s guide - US Post News
CERo Therapeutics Holdings, Inc. Presents Encouraging - GlobeNewswire
CERo Therapeutics reveals promising preclinical ovarian cancer study - Investing.com
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting - The Manila Times
Looking for Exposure to NFLX? Try These Two ETFs - The Globe and Mail
CERo Therapeutics reports positive preclinical results for cancer treatment - Investing.com India
CERo Therapeutics Announces Promising Preclinical Results for CER-1236 in Ovarian Cancer at 2025 SITC Spring Scientific Presentation - Nasdaq
Breakthrough: CERo's Novel Cancer Treatment Targets Ovarian Cancer With Zero Toxicity - StockTitan
CERO stock plunges to 52-week low at $1.31 amid market challenges - Investing.com Australia
CERO stock plunges to 52-week low at $1.31 amid market challenges By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
CERo Therapeutics Holdings, Inc. Announces Progress in - GlobeNewswire
Will This New AML Treatment Strategy Transform Blood Cancer Therapy? CERo Takes Critical Step - StockTitan
CERo Therapeutics to Present Preclinical Data on CER-1236 for Ovarian Cancer at SITC Conference - Nasdaq
CERo Therapeutics Holdings, Inc. to Present Data at the - GlobeNewswire
Can CERo's Cancer-Fighting T Cells Transform Ovarian Cancer Treatment? New Data Coming March - StockTitan
3 Companies Buying Back Stock – Why They’re Doubling Down - The Globe and Mail
CERO stock touches 52-week low at $1.52 amid market challenges - Investing.com Canada
CERO stock touches 52-week low at $1.52 amid market challenges By Investing.com - Investing.com South Africa
Cero Therapeutics Holdings Inc Stock (CERO) Financials Data
There is no financial data for Cero Therapeutics Holdings Inc (CERO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Cero Therapeutics Holdings Inc Stock (CERO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YK Bioventures Opportunities G | 10% Owner |
Dec 12 '24 |
Sale |
0.07 |
1,614,541 |
113,018 |
16,004,077 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 11 '24 |
Sale |
0.08 |
1,343,801 |
107,504 |
17,618,618 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 06 '24 |
Sale |
0.12 |
1,236,874 |
148,425 |
21,383,909 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 10 '24 |
Sale |
0.09 |
1,570,947 |
141,385 |
18,962,419 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 09 '24 |
Sale |
0.11 |
850,543 |
93,560 |
20,533,366 |
| SLOAN STUART M | 10% Owner |
Sep 25 '24 |
Sale |
0.10 |
532,486 |
55,538 |
21,067,956 |
| YK Bioventures Opportunities G | 10% Owner |
Oct 10 '24 |
Sale |
0.10 |
3,250,000 |
325,000 |
22,620,783 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):